Bausch + Lomb announced that two first-in-class pharmaceutical pipeline candidates will advance to the next stages of clinical development following positive trial results. The dual-action dry eye drop combining lifitegrast and perfluorohexyloctane will move into Phase 3 with Day 15 as the primary endpoint, after a Phase 2 study showed a statistically significant reduction in corneal staining at that time point, and the company estimates peak sales potential of approximately $700 million. BL1332, a topical TRPV1 antagonist for ocular surface pain, will continue in Phase 2 following a Phase 1b study that demonstrated a statistically significant reduction in pain intensity, with peak sales potential estimated at approximately $1.4 billion. Shares of Bausch + Lomb inched up 0.5% following the announcement, and the company currently has a market capitalization of $6.16 billion.
Veracyte Inc
West Pharmaceutical Services IncBausch + Lomb CorpPositive Phase 2 and Phase 1b trial results for two pipeline candidates advancing to next stages.
Globus Medical